News

Novartis: Q2 Earnings Snapshot
BASEL, Switzerland (AP) — BASEL, Switzerland (AP) — Novartis AG (NVS) on Thursday reported second-quarter earnings of $4.04 billion. The Basel, Switzerland-based company said it had profit of $2.06 ...
The National Institute for Health and Care Excellence1h
Thousands more breast cancer patients to benefit from new NHS treatment
Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...
Europe markets open: stocks rise; EasyJet cites strike costs
This upbeat corporate news appears to be outweighing lingering concerns about US trade policy and providing a positive start ...
DPA International on MSN1h
Swiss pharma giant Novartis reports Q2 profit increase
Swiss drug major Novartis reported an increase in net income in the second quarter of 2025 on Thursday. Net income ...
Novartis lifts full-year profit forecast, announces $10 billion share buyback
Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key products, including its breast cancer drug Kisqali, during a strong second quarter ...
Medical Dialogues2h
Novartis names Mukul Mehta as CFO
Basel: Novartis has announced the appointment of Mukul Mehta as the Chief Financial Officer (CFO) and a member of the ...
Dow Jones Top Company Headlines at 3 AM ET: TSMC Profit Surges to Record Despite Tariff Cloud | Novartis ...
The airline reset its profit guidance for the year, citing improved travel appetite after economic turmoil and flight disruptions depressed bookings this spring. David Solomon, Brian Moynihan and Jane ...
Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook — Update
For the second quarter, Entresto sales climbed 22% at constant currency to $2.36 billion, contributing to a 11% increase for the group as a whole to $14.05 billion. Novartis cited Kisqali and Entresto ...
Novartis nudges up 2025 earnings forecast on strong second quarter
Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products ...
Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook
The pharmaceutical company raised its full-year profit guidance after continued demand for key drugs fueled growth in ...
EconoTimes3h
Novartis Q2 Net Income Jumps 24% on Strong U.S. Sales and Blockbuster Drugs
Novartis (SIX:NOVN) reported a 24% surge in Q2 net income to $4 billion, driven by robust demand for key therapies like Kisqali, Entresto, and Kesimpta. Earnings per share rose 29% to $2.07, supported ...
Novartis4h
Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance
Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...